hepatitis B

Gilead and Assembly Bio ink antiviral deal

Gilead strikes $100 million deal with Assembly Bio for antiviral assets

Anika Sharma

Gilead Sciences is taking a unique approach to secure early access to Assembly Biosciences’ promising programs. Instead of an outright ...

antios therapeutics shutdown, ati-2173 fda clinical hold, hepatitis b drug antios, antios assembly biosciences collaboration, antios investors return money, ati-2173 phase 2a trial results, hepatitis b drug development challenges

Antios shuts down after FDA halts its hepatitis B drug ATI-2173

Anika Sharma

Antios Therapeutics, a biotech company focused on viral diseases, ceased its operations earlier this year following an FDA-imposed hold on ...

Arbutus Biopharma, COVID-19, hepatitis B, RNA degradation, preclinical data,

Arbutus scraps COVID-19 and RNA degradation programs after disappointing preclinical results

Anika Sharma

Arbutus Biopharma has made significant strategic shifts by discontinuing its involvement in COVID-19 research and RNA destabilizer programs, redirecting its ...

Biktarvy: The Breakthrough HIV Drug That Works for Everyone

Biktarvy Continues to Show Safety and Efficacy Across Diverse Populations Impacted by the Global HIV Epidemic: Updated Findings from IAS 2023

SG Tylor

Source – Gilead Gilead Sciences, has released the results of several studies further solidifying Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir ...